Eupraxia Pharmaceuticals Inc. (TSX:EPRX)

Market Cap	269.34M
Revenue (ttm)	n/a
Net Income (ttm)	-40.07M
Shares Out	35.96M
EPS (ttm)	-1.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47,270
Average Volume	25,250
Open	7.50
Previous Close	7.45
Day's Range	7.44 - 7.60
52-Week Range	3.07 - 8.13
Beta	1.54
RSI	55.59
Earnings Date	Aug 8, 2025

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company’s proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unmet medical needs and pain relief for knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 33
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: EPRX

Financial Performance

Financial numbers in USD